FRED HUTCHINSON CANCER RESEARCH CENTER 
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE 
DEPARTMENT OF MEDICINE, DIVISION OF ONCOLOGY 
(5/9/91) 
Consent to Participate in a Study to Evaluate the Use of Recombinant Human G-CSF Stimulated 
Peripheral Blood Progenitor Cell Supplementation in Autologous Bone Marrow Transplantation in 
Patients with Lymphoid Malignancies 
Investigators : W. Bensinger, M.D., Associate Professor of Medicine, UW, Associate Member, FHCRC 
(667-4933); John Nemunaitis, M.D., Associate in Clinical Research, FHCRC; J. Singer, M.D., Professor 
of Medicine, UW, Member, FHCRC (764-2709); C.D. Buckner, M.D., Professor of Medicine, UW, 
Member, FHCRC (667-4324); Associates: F.R. Appelbaum, M.D., Professor of Medicine, UW, 
Member, FHCRC (667-4412); R. Storb, M.D., Professor of Medicine, UW, Member, FHCRC (667- 
4407); Scott Rowley, M.D., Associate Member, FHCRC (667-4416); E.D. Thomas, M.D., Professor of 
Medicine, UW, Member, FHCRC (667-4329); JA.. Hansen, M.D., Professor of Medicine, UW, 
Director, Clinical Research, FHCRC (667-5111), Lloyd Fisher, Ph.D., Professor of Biostatistics, UW, 
Member, FHCRC. 
24-hour, phone 206/6^7-5001. Study Nurse 583-1986. 
Attending Physician Phone 
BACKGROUND and PURPOSE 
Bone marrow transplantation involves treatment with chemotherapy and radiation that destroy your 
own marrow. Your frozen marrow is then thawed and given back to you. There is then a period of 
approximately 2 weeks when the white blood cell level in your peripheral blood is very low. It takes 
another 2 weeks to recover production of your platelets (the part of your blood that forms clots). 
During this time you are very susceptible to infection or bleeding. 
Some preliminary studies have shown that by giving patients previously frozen peripheral blood cells at 
the time their marrow is given back to them the time to recovery of white cell and platelet production 
can be shortened. This could mean fewer infections or bleeding complications and earlier discharge 
from the hospital. 
The purpose of this research study is to use a growth factor (rhG-CSF), a substance that may stimulate 
"marrow-like" cells in the peripheral blood, to increase the chance of collecting enough peripheral blood 
cells so that recovery time after transplant is shortened. RhG-CSF is also used after transplant to 
accelerate the recovery of the white blood cells. 
PROCEDURES 
Your bone marrow will be harvested and stored and then you will receive seven daily doses of rhG-CSF 
administered by injection into the skin. Before you receive the 5th dose of rhG-CSF, you will undergo 
' e first of four daily peripheral blood cell collections through the Hickman line. These are done on 
[354] 
Recombinant DNA Research, Volume 16 
